Drug Profile
Research programme: cytomegalovirus infection antivirals - Inhibitex
Latest Information Update: 13 Jul 2009
Price :
$50
*
At a glance
- Originator FermaVir Pharmaceuticals
- Developer Inhibitex
- Class Nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 13 Jul 2009 No development reported - Preclinical for Cytomegalovirus infections in USA (unspecified route)
- 20 Sep 2007 Preclinical trials in Cytomegalovirus infections in USA (unspecified route)